(S)-3-benzyl-1-(3,5-dimethylbenzyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione | 951326-71-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (S)-3-benzyl-1-(3,5-dimethylbenzyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione
• CAS: 951326-71-9
• 化学式: C₂₅H₂₄N₂O₂
• 分子量: 384.478
• InChiKey: LISZNCVLLIIQNT-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.19
• 重原子数：
  29.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.41
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  (S)-3-benzyl-1-(3,5-dimethylbenzyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione 、 3-溴丙烯 在 aluminum oxide 、 potassium fluoride 作用下， 以 乙二醇二甲醚 为溶剂， 反应 48.0h， 以81%的产率得到(S)-4-allyl-3-benzyl-1-(3,5-dimethylbenzyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors

  摘要：

  New histone deacetylase inhibitors have been synthesized and evaluated for their activity against non-small lung cancer cell line H661. These compounds have been designed with diversely substituted 1,4-benzodiazepine-2,5-dione moieties as cyclic peptide mimic cap structures, and a hydroxamate side chain. Biological evaluations demonstrated that benzodiazepine-based HDACi bearing an aromatic substituent at the N1 position exhibited promising anti proliferative and HDAC-inhibitory activities. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.067
• 作为产物：
  描述：

  3,5-二甲基溴苄 、 (S)-3-benzyl-3,4-dihydro-1H-benzo[1,4]diazepine-2,5-dione 在 aluminum oxide 、 potassium fluoride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以55%的产率得到(S)-3-benzyl-1-(3,5-dimethylbenzyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors

  摘要：

  New histone deacetylase inhibitors have been synthesized and evaluated for their activity against non-small lung cancer cell line H661. These compounds have been designed with diversely substituted 1,4-benzodiazepine-2,5-dione moieties as cyclic peptide mimic cap structures, and a hydroxamate side chain. Biological evaluations demonstrated that benzodiazepine-based HDACi bearing an aromatic substituent at the N1 position exhibited promising anti proliferative and HDAC-inhibitory activities. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.067